We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+32.34%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$754M
AUM Growth
–
Cap. Flow
+$695M
Cap. Flow
% of AUM
92.12%
Top 10 Holdings %
Top 10 Hldgs %
69.88%
Holding
29
New
28
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$89.9M |
| 2 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$56.9M |
| 3 |
SGMO
SANGAMO THERAPEUTICS INC
SGMO
|
+$46.8M |
| 4 |
KERX
Keryx Biopharmaceuticals Inc
KERX
|
+$44.2M |
| 5 |
Novavax
NVAX
|
+$37.2M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.29% |
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q2 2013 Portfolio in Review
Q2 2013 is the first quarter with a 13F filing on record for RA Capital Management, which disclosed 29 positions worth $754M. Its ten largest holdings account for 70% of the portfolio.
Its largest position is Acadia Pharmaceuticals: 6,529,810 shares worth $119M.
By sector, the portfolio is most concentrated in Healthcare at 71% of assets.
- RA Capital Management's largest Q2 2013 buy was Acadia Pharmaceuticals: 6,529,810 shares worth $119M.
- RA Capital Management's ten largest holdings make up 70% of its $754M portfolio in Q2 2013.
- RA Capital Management disclosed 29 positions in Q2 2013, its first 13F filing on record.
Based on RA Capital Management's 13F filing for Q2 2013, filed 14 Aug 2013.